• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Processa Pharmaceuticals, Inc. - Common Stock (NQ:PCSA)

    2.230 -0.150 (-6.30%)
    Streaming Delayed Price Updated: 11:46 AM EST, Feb 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Processa Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    News headline image
    Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    News headline image
    TOMI Environmental (NASDAQ: TOMZ) | Listeria in Packaged Meals – A Public Health Alert! More Stocks Inside
    Via AB Newswire
    Topics Death Lawsuit Product Recall
    News headline image
    Peraso Inc. (NASDAQ: PRSO) Signals Turnaround – Reports Financials August 11, 2025 – More Stocks Inside
    Via AB Newswire
    News headline image
    Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
    From Processa Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    News headline image
    Peraso Inc (NASDAQ: PRSO) Deploys Stealth Tech Shipment for Military Use – Tapping $500M NATO Market – More Stocks Inside
    Via AB Newswire
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Phase 2 Clinical Trial Dosing Has Commenced
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2024 Financial Results, Provides Updates
    Via Investor Brand Network
    BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) IND Application for Phase 2 Clinical Trial of NGC-Cap in Patients with Breast Cancer Receives FDA Clearance
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Seasoned Veteran as Chief Financial Officer
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Efficacy Results from Phase 1b Trial
    Via Investor Brand Network
    BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Dr. Steven Cha to Lead Clinical Development of Oncology Programs
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
    Via Investor Brand Network
    BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
    Via Investor Brand Network
    TinyGemsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering
    Via Investor Brand Network
    Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
    Via AB Newswire
    Topics Retirement
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering
    Via Investor Brand Network
    News headline image
    Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
    From Processa Pharmaceuticals, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Plans to Expand NGC-Cap Program into Advanced or Metastatic Breast Cancer
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces 1-for-20 Reverse Stock Split
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Biotech Showcase 2024
    Via Investor Brand Network
    InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Provides Interim Analysis from Phase 1b NGC-Cap Trial
    Via Investor Brand Network
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.